Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Desoximetasone
Overview
What is Desoximetasone?
Desoximetasone cream USP, 0.25% contains the active synthetic corticosteroid desoximetasone, USP. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.
Each gram of desoximetasone cream USP, 0.25% contains 2.5 mg of desoximetasone, USP in an emollient cream base consisting of cetostearyl alcohol, edetate disodium, isopropyl myristate, lanolin alcohol, mineral oil, purified water, and white petrolatum.
The chemical name of desoximetasone, USP is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-,(11β,16α)-. Desoximetasone, USP has the molecular formula CHFO and a molecular weight of 376.47. The CAS Registry Number is 382-67-2.
The structural formula is:
What does Desoximetasone look like?
What are the available doses of Desoximetasone?
Sorry No records found.
What should I talk to my health care provider before I take Desoximetasone?
Sorry No records found
How should I use Desoximetasone?
Desoximetasone cream USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Apply a thin film of desoximetasone cream USP, 0.25% to the affected skin areas twice daily. Rub in gently.
What interacts with Desoximetasone?
Sorry No Records found
What are the warnings of Desoximetasone?
Sorry No Records found
What are the precautions of Desoximetasone?
Sorry No Records found
What are the side effects of Desoximetasone?
Sorry No records found
What should I look out for while using Desoximetasone?
Desoximetasone cream USP, 0.25% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Keep out of reach of children.
What might happen if I take too much Desoximetasone?
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see ).
How should I store and handle Desoximetasone?
Store at room temperature between 20C to 25C (68F to 77F), with excursions permitted between 15C to 30C (59F to 86F). Do not store in the refrigerator or freezer. Use nosepiece immediately after removing from foil pouch.Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046Desoximetasone cream USP, 0.25% is available as follows:15 gram tube: NDC 0472-0478-1560 gram tube: NDC 0472-0478-60Store at controlled room temperature between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]Manufactured by:G&W Laboratories, Inc.111 Coolidge StreetSouth Plainfield, NJ 07080 USA Distributed by:Actavis Pharma, Inc.Parsippany, NJ 07054 USARevised - July 2015I600-6270/71 GW 7046
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.
The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Non-Clinical Toxicology
Desoximetasone cream USP, 0.25% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.Keep out of reach of children.
Specific trials studying the interaction between ropivacaine and class III antiarrhythmic drugs (eg, amiodarone) have not been performed, but caution is advised (see ).
Ropivacaine hydrochloride should be used with caution in patients receiving other local anesthetics or agents structurally related to amide‑type local anesthetics, since the toxic effects of these drugs are additive. Cytochrome P4501A2 is involved in the formation of 3‑hydroxy ropivacaine, the major metabolite. , the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYPIA2 inhibitor. Thus strong inhibitors of cytochrome P4501A2, such as tluvoxamine, given concomitantly during administration of ropivacaine hydrochloride, can interact with ropivacaine hydrochloride leading to increased ropivacaine plasma levels. Caution should be exercised when CYPlA2 inhibitors are coadministered. Possible interactions with drugs known to be metabolized by CYPlA2 via competitive inhibition such as theophylline and imipramine may also occur. Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in plasma clearance of ropivacaine.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.
Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.
An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.
Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.
Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.
Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
In controlled clinical studies the incidence of adverse reactions were low (0.8%) for desoximetasone cream USP, 0.25%, and included burning, folliculitis, and folliculo-pustular lesions.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
517Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).